#Calithera Biosciences Inc

[healthcarehubhh]

Cancer Metabolism-Based Therapeutics Market to Exhibit Robust Growth Owing to High Investment in R&D Activities by Key Players

The cancer metabolism-based therapeutics market has witnessed significant growth in recent years. Cancer metabolism-based therapeutic is an emerging field that uses altered metabolic pathways in cancer cells as targets for therapy. Some of the key advantages of targeting cancer cell metabolism include increased selectivity, reduced drug resistance, and decreased toxicity. Cancer metabolism reprogramming enables cancer cells to support high biosynthetic and bioenergetic demands for rapid proliferation. The increasing understanding of cancer metabolism has facilitated the development and clinical testing of several metabolism-based anti-cancer drugs. The global cancer metabolism-based therapeutics market is estimated to be valued at US$ 210.2 billion in 2024 and is expected to exhibit a CAGR of 95% over the forecast period 2023 to 2030. Key Takeaways - Key players like Calithera Biosciences, Inc. and Celgene Corporation are undertaking extensive R&D activities to develop novel cancer metabolism-based therapeutics such as inhibitors against metabolic enzymes and transporters. - There is growing demand for cancer metabolism-based therapeutics owing to the increasing cancer incidence worldwide and limitations of existing cancer treatments. - Technological advancements such as metabolomics and systems biology approaches have enhanced understanding of cancer metabolism pathways, facilitating development of new drug targets. Market Trends - Increased focus on developing combination therapies using cancer metabolism drugs along with conventional treatments to achieve better outcomes. - Emergence of artificial intelligence and machine learning for improved target identification, drug repurposing, and precision oncology using cancer metabolism biomarkers. Market Opportunities - Significant scope for research and development of novel therapeutics targeting various altered metabolic pathways in different cancer types. - Untapped potential in developing countries presents lucrative growth opportunities for leading players. Impact of COVID-19 on Cancer Metabolism Based Therapeutics Market Growth The COVID-19 pandemic has significantly impacted the cancer metabolism based therapeutics market. During the initial phase of the pandemic, patient visits and routine cancer screenings significantly declined due to lockdowns and patient concerns over exposure. This led to late stage cancer diagnoses becoming more common. The demand for critical cancer therapies also initially dropped in 2020. However, the market rebounded in 2021 as healthcare systems adapted protocols for COVID-safe care and patients regained confidence in seeking treatment. While the pandemic disrupted clinical trials and drug development temporarily, it also highlighted the need to develop more targeted and personalized therapies. Cancer metabolism is now recognized as an important area of research that could lead to therapies tailored to individual cancer metabolic profiles. Pharmaceutical companies are investing more in research related to metabolic pathways and metabolomics to identify predictive biomarkers and new drug targets. Telehealth and digital health solutions also saw increased adoption to facilitate remote patient monitoring and care during the pandemic. These tech-enabled approaches are enabling more efficient clinical trials and care management going forward. Geographical Regions with Highest Market Concentration North America accounts for the largest share of the global cancer metabolism based therapeutics market currently, both in terms of value and volume. This is due to the presence of major pharmaceutical players, high health expenditure, advanced healthcare infrastructure and higher adoption of new cancer drugs in the region. Within North America, the United States holds the major market share currently.

[readnutrition]

Cramer's lightning round: BlackRock is a buy

Cramer’s lightning round: BlackRock is a buy

[ad_1]

Micron Technology: “This stock shouldn’t have been down yesterday, Zack. That was crazy. I think it’s a great opportunity. Maybe get it at $48. It’ll really be a steal.”

Everquote: “It’s another one. There’s a lot of companies that all they do is they get to the lowest price in insurance and people just — they love these companies.”

Marvell Technology: “It’s our favorite 5G play. It…

[ustribunenews-blog]

(Nasdaq:CALA) Calithera Biosciences Inc Closed Today On 52 Week Low Note

(Nasdaq:CALA) Calithera Biosciences Inc Closed Today On 52 Week Low Note

Calithera Biosciences Inc (Nasdaq:CALA)

July 11th, 2018

Amidst falling markets Calithera Biosciences Inc finished Wednesday’s trading session down 8.51%, a $0.40 decrease to close on $4.30. Sadly, in addition to dropping CALA ended up closing the day at a new 52 week low.As well as the drop in value, Calithera Biosciences Inc hit a new 52 week low of $4.30, breaking the previous low of $4.68 from…

[ramshariraut]

Gastrointestinal Stromal Tumor (GIST) Drug  Market Growth Cycle to Mitigate New Business Opportunity

Global Gastrointestinal Stromal Tumor (GIST) Drug  Market, Geography (North America (United States, Canada and Mexico), South America (China, Japan, Korea, India and Southeast Asia), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), Middle East and Africa (Saudi Arabia, Egypt, Nigeria and South Africa)) Industry Trends 2021-2028

<strong>Market Overview</strong> The research study of the Gastrointestinal Stromal Tumor (GIST) Drug  market is designed on account of the fact that each segment is individually evaluated and then combined to form the whole market, and the analysis is done according to customers’ needs. The Gastrointestinal Stromal Tumor (GIST) Drug  market is made to receive high growth in the forecast period due to fast-paced industrialization and urbanization in the developing countries. Moreover, strengthening traffic infrastructure projects and micro-tunneling activities are further expected to drive the growth of the Gastrointestinal Stromal Tumor (GIST) Drug  market. However, high investment costs may affect the overall market growth. Besides, increasing applicability in the mining industry and technological advancements are likely to reflect various significant chances for the key players operating in the Gastrointestinal Stromal Tumor (GIST) Drug  market during the forecast period.

Request a sample Report of Gastrointestinal Stromal Tumor (GIST) Drug  Market @ <a href=https://www.statistifymarketresearch.com/reports/gastrointestinal-stromal-tumor-gist-drug-market/sample-request-87400>https://www.statistifymarketresearch.com/reports/gastrointestinal-stromal-tumor-gist-drug-market/sample-request-87400</a>

<strong>Methodology</strong> Primary and secondary research methods are examined to follow the entire scientific research systematically. Primary research consists of raw material supply, industry status, and other indexes while secondary research includes divisions according to industry conditions and key innovations related to the Gastrointestinal Stromal Tumor (GIST) Drug  market. The report is based on various research techniques. Substantial qualitative, as well as quantitative research, is done along with an entire marketing procedure to record the key features.

<strong>Market Segmentation</strong> The segmentation of the global Gastrointestinal Stromal Tumor (GIST) Drug  industry is carried out in this report based on various variables, such as scale, framework, business, and end-use area. In addition, each segment is established along with growth analysis to provide all the important details for the forecast period. The regional summary provides an estimation of the quantity and revenues of each region, along with its respective nations. The work also includes numerous facets of the industry, such as import & export, supply chain valuation, Gastrointestinal Stromal Tumor (GIST) Drug  market share, sales, volume, and so on. In addition, the research examines market-influencing considerations that include production processes and methodologies, development networks, and the product model. This study would certainly provide you with an unmistakable glimpse into any particular business fact without having to refer to any other research paper or source of knowledge. Our research will give you all the information on the history, current, and future fate of the sector in question.

<strong>Report Summary</strong> Any sort of report in an organization is a valuable and important tool regardless of the scale on which it operates. It provides a method to track and examine the performance and overall circumstances of the business while identifying areas that require improvement for the better functioning of the organization. A  business report also holds great importance in the fact that it suggests corrective actions that need to be done to avoid the business fails to meet the desired targets and thus helps to recover in times of adversities. An annual report prepared in the company is an effective tool for providing management, employees, investors, and other clients with a complete picture of their business.

<strong>Reasons to buy this report:</strong> Detailed analysis of key factors and opportunities available in different segments for strategizing. Detailed analysis of the latest trends and forecasts to create a plan for the next step. Detailed analysis of various segments and their driving factors such as growth rate and revenue is offered. A thorough analysis of each geographic region can help market players devise expansion strategies and gain from the opportunity. This study presents the analytical depiction of the Gastrointestinal Stromal Tumor (GIST) Drug  industry along with the current trends and future estimations to determine the imminent investment pockets. The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the Gastrointestinal Stromal Tumor (GIST) Drug  market share.

<strong> <a href=https://www.statistifymarketresearch.com/checkout/?currency=USD&type=single_user_license&report_id=87400>Do Inquiry Before Purchasing Gastrointestinal Stromal Tumor (GIST) Drug  Market  Report</a></strong>

<strong>Top Listed Companies in the Gastrointestinal Stromal Tumor (GIST) Drug  Market Include</strong>

Ariad Pharmaceuticals, Inc.,Chipscreen Biosciences Ltd,Astex Pharmaceuticals, Inc.,Arog Pharmaceuticals, Inc.,Calithera Biosciences, Inc.,Array BioPharma Inc.,F. Hoffmann-La Roche Ltd.,Boston Biomedical, Inc.,Blueprint Medicines Corporation,Deciphera Pharmaceuticals, LLC,Natco Pharma Limited,Omeros Corporation,Horizon Pharma Plc,Nerviano Medical Sciences S.r.l.,Kolltan Pharmaceuticals, Inc.,Immunicum AB,Novartis AG,Jiangsu Hengrui Medicine Co., Ltd.

<strong>Regional Analysis</strong> North America, Latin America, Asia-Pacific nations, Europe, India, China, Australia, and a lot of other countries of the world have been scaled on various parameters and thereafter a report is being made on them. It is observed that North America, will show positive development during the period in marketing development. Administrative organizations and marketing managers are trying to channelize and integrate all the effort toward developing an efficient marketing system. As the important parts of the market business would spread all around the world, Middle East, Africa, North America along other Asia-Pacific nations shows great signs of developing a good market-oriented environment in their area. Customization of the report: The customized report is provided by our consultancy at a reasonable price. We provide updated information according to the requirements of the customers in the market world.

<strong>Benefits:</strong> 1. Well updated information. 2. Statistical report provided. 3. Discount offer in customization. 4. Service at the global level. 5. Company research report provided.

<strong>Services:</strong> 1. Expert analysts at your service. 2. Service according to your needs 3. Clearance of your queries. 4. Whole day service 5. Well updated Report.

Full Report Summary of Gastrointestinal Stromal Tumor (GIST) Drug  Market @ <a href=https://www.statistifymarketresearch.com/gastrointestinal-stromal-tumor-gist-drug-market>https://www.statistifymarketresearch.com/gastrointestinal-stromal-tumor-gist-drug-market</a>

<strong>About Statistify Market Research</strong> Statistify Market Research focuses on some basic research techniques of exploratory research, descriptive research, and casual research. In exploratory research in-depth interviews and discussion groups are used to better define a problem of scout opportunities. The descriptive research methods include personal interaction and surveys used to access a situation in the marketplace ( i.e., the potential for a specific product or consumer attitudes). The causal research is conducted through estimation and is used for testing cause and effect relationships. This research design is a framework or blueprint for conducting the marketing research project.

<strong>Company Name - Statistify Market Research</strong> Office Address - 156, Sector 9 Vasundhra Aptts Rohini, New Delhi 110085 IN Telephone Numbers - (+44) 162-237-1047 (+44) 162-237-1047 Email ID - <a href="mailto:sales@statistifymarketresearch.com"><strong>sales@statistifymarketresearch.com</strong></a> Contact Us – <a href="https://www.statistifymarketresearch.com/contact-us/"><strong>https://www.statistifymarketresearch.com/contact-us/</strong></a>

[ericvick]

Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data

Here’s a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Jan. 4)

ABIOMED, Inc. (NASDAQ: ABMD)

Arvinas Inc (NASDAQ: ARVN)

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

Bioanalytical Systems, Inc. (NASDAQ: BASI)

BioNano Genomics Inc (NASDAQ: BNGO) (said its subsidiary Lineagen’s genetic tests identified novel variants in known autism risk genes)

BridgeBio Pharma Inc (NASDAQ: BBIO)

Clearpoint Neuro Inc (NASDAQ: CLPT)

Curis, Inc. (NASDAQ: CRIS)

DiaMedica Therapeutics Inc (NASDAQ: DMAC)

Eidos Therapeutics Inc (NASDAQ: EIDX) (proxy advisory firm Institutional Shareholder Services recommended Eidos merger with BridgeBio)

Endo International PLC (NASDAQ: ENDP)

Fulgent Genetics Inc (NASDAQ: FLGT)

I-Mab ADR (NASDAQ: IMAB)

Jaguar Health Inc (NASDAQ: JAGX)

Masimo Corporation (NASDAQ: MASI)

Ocugen Inc (NASDAQ: OCGN) (reacted to its Indian partner receiving conditional approval for coronavirus vaccine in the Indian market)

Organogenesis Holdings Inc (NASDAQ: ORGO)

Otonomy Inc (NASDAQ: OTIC)

PMV Pharmaceuticals Inc (NASDAQ: PMVP)

PRA Health Sciences Inc (NASDAQ: PRAH)

Precigen Inc (NASDAQ: PGEN)

Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN)

TRACON Pharmaceuticals Inc (NASDAQ: TCON)

United Therapeutics Corporation (NASDAQ: UTHR)

Vincera Pharma Inc (NASDAQ: VINC)

Vistagen Therapeutics Inc (NASDAQ: VTGN)

X T L Biopharmaceuticals Ltd (ASDAQ: XTLB)

Down In The Dumps

(Biotech Stocks Hitting 52-week Lows Jan. 4)

4D Molecular Therapeutics Inc (NASDAQ: FDMT)

Aprea Therapeutics Inc (NASDAQ: APRE)

Calithera Biosciences Inc (NASDAQ: CALA) (reported adverse outcome for the Phase 2 study of telaglenastat in patients with advanced or metastatic renal cell carcinoma)

Intercept Pharmaceuticals Inc (NASDAQ: ICPT)

Vivos Therapeutics Inc (NASDAQ: VVOS)

Stocks In Focus Moderna Gets Israeli Regulatory Nod For Coronavirus Vaccine Candidate

Moderna Inc (NASDAQ: MRNA) announced that Israel’s Ministry of Health has given authorization to import Moderna’s mRNA-1273, its vaccine candidate against the novel coronavirus. 

Story continues

“This is the third regulatory authorization for the COVID-19 Vaccine Moderna, and its first outside of North America,” said Stéphane Bancel, CEO of Moderna.

“We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”

Israel has secured 6 million doses of mRNA-1273 and first deliveries are expected to begin shortly, the company said.

The stock was up 1.14% to $113 in premarket trading. 

Roche’s Cancer Drug Combo Gets Breakthrough Therapy Designation For Lung Cancer

Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA granted breakthrough therapy designation for tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, in combination with Tecentriq for the first-line treatment of people with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations

The stock edged up 0.22% to $44 in after-hours trading.

Gritstone Oncology Rallies On Insider, Fund Buying

Gritstone Oncology Inc (NASDAQ: GRTS) shares rallied in reaction to a filing which revealed that biotech-focused hedge fund EcoR1 Capital, LLC built up a 9.9% stake in the company.

A separate filing showed Thomas Woiwode, a member of the company’s board of directors, bought 1.35 million shares in the company at $3.71 each. 

The stock was jumping 19.16% higher to $4.85 premarket Tuesday. 

Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates

Tonix to Collaborate With Massachusetts General Hospital For Organ Transplant Rejection Treatment

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) announced the signing of a second research collaboration agreement with Massachusetts General Hospital to develop TNX-1500, a humanized monoclonal antibody that targets the CD40-ligand for the prevention and treatment of organ transplant rejection.

In premarket trading Tuesday, Tonix shares were jumping 8.39% to 78 cents.

Marker Announces Lifting of Clinical Hold On Acute Myeloid Leukemia Study

Marker Therapeutics, Inc. (NASDAQ: MRKR) said the FDA lifted the partial clinical hold on its Phase 2 trial investigating the safety and efficacy of MT-401, its lead, multi-tumor-associated, antigen-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia.

BioXcel Says BXCL501 Aces Phase 1b/2 Study In Treating Dementia-Related Agitation

BioXcel Therapeutics Inc (NASDAQ: BTAI) said its BXCL501, an orally dissolving thin film formulation of dexmedetomidine, met the primary and secondary endpoints of the TRANQUILITY Phase 1b/2 trial that evaluated the pipeline asset at the 60 mcg dose level for treating agitation related to dementia, including Alzheimer’s disease.

Topline results from the evaluated doses showed that BXCL501 was generally well-tolerated, with rapid and durable reductions observed in measures of acute agitation with the 60 mcg dose. 

The stock was moving up 7.77% to $56.31 in premarket trading Tuesday.

Myovant’s Recently Approved Prostate Cancer Treatment Now Available In US

Myovant Sciences Ltd (NYSE: MYOV) announced the U.S. commercial availability of Orgovyx, the first and only oral gonadotropin-releasing hormone receptor antagonist approved by the FDA, for the treatment of adult patients with advanced prostate cancer.

In premarket trading Tuesday, Myovant shares were adding 3.06% to $25.59. 

Checkmate Names Pharma Industry Veteran Robert Dolski As CFO

Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) announced the appointment of biopharma industry veteran Robert Dolski as its chief financial officer.

The company also said it recently strengthened its leadership team by naming Katherine Eade as General Counsel.

aTyr’s Lead Candidate Aces Midstage Study In Hospitalized COVID-19 Patients

aTyr Pharma Inc (NASDAQ: LIFE) announced positive topline results from its Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923, in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation.

The trial met its primary endpoint of safety, demonstrating that a single, intravenous dose of ATYR1923 was generally safe and well-tolerated in both the 1.0 and 3.0 mg/kg treatment groups, with no drug-related serious adverse events, the company said.

“We are very encouraged by the signal of clinical activity seen in the 3.0 mg/kg cohort of ATYR1923. The relatively faster time to recovery seen by adding a single dose of ATYR1923 to standard of care treatment and the greater proportion of patients recovering within a week compared to placebo give us further confidence in this signal,” said Sanjay Shukla, CEO of aTyr.

The stock was up 6.8% premarket at $4.24. 

Zosano Requests FDA Meeting On Migraine Drug Application

Zosano Pharma Corp (NASDAQ: ZSAN) said on Dec. 30 that the company requested a Type A meeting with the FDA.

The purpose of the Type A meeting is to receive FDA input on the requirements for the resubmission of the NDA for its migraine treatment candidate Qtrypta following the complete response letter received on Oct. 20.

The FDA typically responds to a sponsor’s request for a Type A meeting, if granted, with a meeting scheduled within 30 days from the receipt of the request.

Zosano shares were trading 42.93% higher at 83 cents premarket Tuesday. 

Cerecor Announces Positive Results Phase 2 Study Of CERC-002 In Hospitalized COVID-19 Patients

Cerecor Inc (NASDAQ: CERC) announced positive results from its exploratory, Phase 2 U.S.-based proof of concept trial of the human anti-LIGHT monoclonal antibody CERC-002 in hospitalized patients with COVID-19 associated pneumonia and mild-to-moderate acute respiratory distress syndrome.

The trial demonstrated robust improvement in the primary endpoint — the proportion of patients alive and free of respiratory failure over the 28-day study period — compared to placebo.

The stock was jumping 24.62% to $3.29 in premarket trading Tuesday.

ImmunoGen Insiders Buy Shares

ImmunoGen, Inc. (NASDAQ: IMGN) shares moved to the upside after a series of filings revealed purchase of the company’s shares by company insiders.

In after-hours trading, the stock gained 5.93% to $6.88.

Puma Biotechnology Shares Drop On Insider Selling

Puma Biotechnology Inc (NASDAQ: PBYI) shares came under pressure after a SEC filing on Form 4 revealed that its CEO Alan Auerbach sold 355 shares in the company at $11.656 per share. A separate filing showed that Richard Bryce, the company’s chief medical and scientific officer sold 92 shares at a price of $11.65 per share.

The stock shed 5.52% to $9.76 in after-hours trading.

Offerings

Generation Bio Co (NASDAQ: GBIO) said in a filing it plans to offer 7.5 million shares of its common stock in a follow-on offering.

In after-hours trading, the stock slipped 4.42% to $28.75.

Fate Therapeutics Inc (NASDAQ: FATE) said it has commenced an underwritten public offering of $350 million in shares of common stock.

The company said it intends to use the net proceeds from the offering to fund clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing operations, the conduct of preclinical R&D, and for general corporate purposes.

The stock was down 4.10% to $86 in after-hours trading.

Prelude Therapeutics Inc (NASDAQ: PRLD) said it has commenced a public offering of 1.75 million shares of its common stock in a follow-on offering. All shares of common stock to be sold in the offering will be sold by the company.

NGM Biopharmaceuticals Inc (NASDAQ: NGM) said it has commenced an underwritten public offering of $100 million in shares of its common stock. All of the shares in the proposed offering will be sold by the company.

In after-hours trading, the stock fell 2.63% to $28.48.

On The Radar Clinical Readouts

Mersana Therapeutics Inc (NASDAQ: MRSN) is scheduled to release updated data from the ovarian cancer cohort of the Phase 1 expansion study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b. The presentation is due at the company’s virtual analyst and investor event.

Related Link: SVB Leerink Bullish On Silverback Therapeutics, Sees Diverse Pipeline

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[pharmanewstrands-blog]

Cancer Metabolism Based Therapeutics Market, By Drug, Indication - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026

According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells. It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.

Request A Sample Copy: http://bit.ly/2FnRjLg

Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types, which is expected to boost the growth of cancer metabolism-based therapeutics market

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

Calithera Biosciences, Inc. announced novel cancer therapeutic drug named CB–839 in 2017. The FDA granted CB-839 as a Fast Track designation drug with the combination of everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is being evaluated in clinical trials phase I and II for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Click To Read More On: Cancer Metabolism Based Therapeutics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:sales@coherentmarketinsights.com

[myabhijitr]

Cancer Metabolism Based Therapeutics Market To Increase at Steady Growth & Forecast 2018 – 2026

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/961

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Get Request Sample Copy of Research Report: www.coherentmarketinsights.com/insight/request-sample/961

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

About Coherent Market Insights:

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link :https://www.coherentmarketinsights.com/phase-xs,

[ustribunenews-blog]

(Nasdaq:CALA) Calithera Biosciences Inc Lowers The 52 Week Low

(Nasdaq:CALA) Calithera Biosciences Inc Lowers The 52 Week Low

Calithera Biosciences Inc (Nasdaq:CALA)

June 11th, 2018

Amidst rising markets Calithera Biosciences Inc finished Tuesday’s trading session down 2.97%, a $0.15 decrease to close on $4.90. In addition to the drop in value, Calithera Biosciences Inc hit a new 52 week low of $4.80, breaking the previous low of $4.85 from earlier this January. Be aware that the Altman Z-Score1 (An indicator of the…

[30mintrade-blog]

Handpicked Daily Growth Stock Ideas to buy now - Feb 24th 2020

CALA - Calithera Biosciences, Inc. MRSN - Mersana Therapeutics, Inc. GSX - GSX Techedu Inc. CVM - CEL-SCI Corporation

#DailyPicks #StockIdeas #TrendFollowingStocks #StockMarketAnalysis #DailyStocks #SwingTrading

[bharatiyamedia-blog]

Arcturus Therapeutics and MYOS RENS Expertise amongst healthcare gainers; Sesen Bio leads the losers - Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT)

http://tinyurl.com/yy5cu5jy Gainers: Melinta Therapeutics (NASDAQ:MLNT) +144%. Arcturus Therapeutics (NASDAQ:ARCT) +35%. MYOS RENS Expertise (NASDAQ:MYOS) +23%. Enlivex Therapeutics (NASDAQ:ENLV) +11%. Harmony Medical Companies (NYSE:CCM) +10%. Losers: Sesen Bio (NASDAQ:SESN) -24%. Genocea Biosciences (NASDAQ:GNCA) -18%. Calithera Biosciences (NASDAQ:CALA) -16%. World Wire Blood (NYSE:CO) -11%. Scholar Rock Holding (NASDAQ:SRRK) -10%. window.SA = {"App":{"name":"SA","fullName":"Seeking Alpha","type":"regular","host":"https://seekingalpha.com","emailHost":"https://email.seekingalpha.com","pro":false,"proPlus":false,"contributorCenter":false,"realHostName":"https://seekingalpha.com","isCms":false,"cancelPV":false,"isSharkPreview":false,"usersOnSite":"7,524,414","assetHosts":["https://static.seekingalpha.com","https://static1.seekingalpha.com","https://static2.seekingalpha.com","https://static3.seekingalpha.com"],"moneData":{},"assetHost":"https://static.seekingalpha.com","userEchoHost":"https://feedback.seekingalpha.com","env":{"dev":false,"staging":false,"production":true,"test":false},"gaAccountId":"UA-1466493-1","comscoreAccountId":8500672,"fbAppId":"624608951014846","twitterAccountName":"SeekingAlpha","rollbarToken":"5edf110be2fc4cecb32637fc421111e2","perimeterXAppId":"PXxgCxM9By","embedlyKey":"a6da93fdfc49472099ce63260954716b","mp":false,"chat":{"host":"https://rc.seekingalpha.com"}},"pageConfig":{"Refresher":{"active":false},"Data":{"mc":{"id":3472412,"title":"Arcturus Therapeutics and MYOS RENS Technology among healthcare gainers; Sesen Bio leads the losers","primaryTicker":"arct","primaryIsCrypto":false,"twitContent":"$MLNT $ARCT $MYOS - Arcturus Therapeutics and MYOS RENS Technology among healthcare gainers; Sesen Bio leads the losers https://seekingalpha.com/news/3472412-arcturus-therapeutics-myos-rens-technology-among-healthcare-gainers-sesen-bio-leads-losers?source=tweet","isSp500":false,"tags":["healthcare","on-the-move","hidden-from-qp"],"closest_trading_day":"2019-06-19","publishDate":"2019/06/19"},"pageType":"single_news","primaryTicker":"arct","indexTickers":{}},"Ads":{"slots":[{"container":"news-left-slot-1","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":160},"size":[[160,600],"fluid"],"str":"160x600,fluid"},"cls":"mb25"},{"container":"news-right-slot-1","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":1},"size":[[300,250],[300,600],"fluid"],"str":"300x250,300x600,fluid"},"cls":"mb25","flex":true},{"container":"news-right-slot-2","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":100},"size":[[300,100]],"str":"300x100"},"cls":"mb25"},{"container":"news-right-slot-3","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":2},"size":[[300,252],"fluid"],"str":"300x252,fluid"},"cls":"mb25","native":true},{"container":"news-middle-slot","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{},"size":[[640,40]],"str":"640x40"},"cls":"mb25"},{"container":"news-bottom-slot","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":728},"size":[[728,90]],"str":"728x90"},"delay":true,"delta":500},{"container":"instream_recommendation_ad","data":{"name":"/6001/sek.market-news/on-the-move/single-post","disable_collapse_empty_div":false,"targeting":{"tile":50},"size":["fluid"],"str":"fluid"},"delay":true,"delta":500}],"testScroll":true,"disabled":false,"kvs":{"d":"market-news","t":["on-the-move","healthcare-news","on-the-move-news"],"mcid":[true,3472412],"tickerbundle":["growth","value","small-cap","healthcare","zacks"],"cnt":["fed","tech","tech2","bny"],"s":["MLNT","ARCT","MYOS","ENLV","CCM","SESN","GNCA","CALA","CO","SRRK"]}},"Paths":{"int":{"adsAPI":{"src":"https://static3.seekingalpha.com/assets/api/ads-0cf8a56f1d93653afa4e33f67b12af5def2cb05353be15eeceffef0ad3d63d2f.js","id":"sa-ads-api"}},"ext":[{"src":"https://js-sec.indexww.com/ht/p/183642-162053219843577.js","id":"ie"},{"src":"https://www.googletagservices.com/tag/js/gpt.js","id":"gpt"},{"src":"https://pub.doubleverify.com/pub.js?ctx=818052u0026cmp=DV157324","id":"doubleverify"},{"src":"https://sb.scorecardresearch.com/beacon.js","id":"sb"},{"src":"https://ssl.google-analytics.com/ga.js","id":"ga"},{"src":"https://connect.facebook.net/en_US/sdk.js","id":"facebook-jssdk"}]},"lastRequested":"2019-06-19 11:06:18 -0400","SlugsPrices":{"disabled":false},"proOpenHouse":{"active":false,"end_date":"2017-03-20T06:00:00.000-04:00"},"proFlashSale":{"active":false,"end_date":"2017-03-23T00:00:00.000-04:00"},"saSource":null,"name":null,"useSQuoteBackup":null,"inFreeArticleTest":false,"featureCampaignVersion":null,"featureCampaignFlow":null,"skipAdoricFeatures":false},"headerConfig":{"noNotificationsMenu":null,"nonFixed":null,"tabless":null,"activeTab":"market-news"},"modules":{},"requires":[],"trackq":[],"exceptions":[],"gptInit":false}; Source link

[healthcaremarket242-blog]

Cancer Metabolism Based Therapeutics Market – Scope and Opportunities Analysis 2018 – 2026

According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells. It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/961

Global Cancer Metabolism Based Therapeutics Market Taxonomy

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories

By Drug –

CPI-613

Enasidenib

By Indication –

Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes (MDS)

Metastatic Renal Cell Carcinoma

Melanoma

Others

Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types, which is expected to boost the growth of cancer metabolism-based therapeutics market

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Click to read more on Cancer Metabolism Based Therapeutics Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

[abrcapfinancial-blog]

EARNING UPDATE $CALA Calithera Biosciences, Inc. for quarter ending q_Jun18 - Revenue grew, Margins expanded

EARNING UPDATE $CALA Calithera Biosciences, Inc. for quarter ending q_Jun18 – Revenue grew, Margins expanded

[s2If !current_user_can(access_s2member_level0)]Please login to read the earning update on CALA [lwa][/s2If][s2If current_user_can(access_s2member_level0)]Calithera Biosciences, Inc. reported earnings (EPS) of -0.09 per share for the quarter ending q_Jun18. This is vis-vis -0.37 per share for the previous quarter ending q_Mar18, a growth of 75.7 %. Compared to last year same quarter (q_Jun17),…

[myabhijitr]

Cancer Metabolism Based Therapeutics Market - Global Industry Insights, 2018–2026

According to the American Cancer Society (ACS), approximately 53,670 people are expected be diagnosed with pancreatic cancer and approximately 43,090 people are expected to die due to pancreatic cancer in the U.S in 2017. As per the ACS, pancreatic cancer accounts for around 3% of all cancers and around 7% of all cancer deaths in the U.S. Moreover, according to Cancer Research UK, approximately 3,072 new cases were diagnosed with acute myeloid leukemia (AML) and around 2,516 deaths were occurred in 2014.

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/961

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories,,By Drug –,,CPI-613,Enasidenib,By Indication –,,Acute Myeloid Leukemia (AML),Myelodysplastic Syndromes (MDS),Metastatic Renal Cell

Read Full Report with TOC @ www.coherentmarketinsights.com/ongoing-insight/toc/961

On the basis of drug and indication, cancer metabolism-based therapeutics market segmented into two categories By Drug – CPI-613, Enasidenib,. By Indication – Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Metastatic Renal Cell Carcinoma, Melanoma, Others,.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

[hillcountrytimes]

Franklin Street Advisors Increased Its Jpmorgan Chase & Co (JPM) Position; WYG PLC (LON:WYG) Covered By 4 Bullish Analysts Last Week

Among 4 analysts covering WYG Plc (LON:WYG), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. WYG Plc had 21 analyst reports since August 13, 2015 according to SRatingsIntel. N+1 Singer maintained the stock with “Corporate” rating in Thursday, September 22 report. The stock has “Buy” rating by WH Ireland on Thursday, November 12. The firm has “Corporate” rating by N+1 Singer given on Friday, October 30. The stock has “Corporate” rating by N+1 Singer on Thursday, December 3. WH Ireland maintained WYG PLC (LON:WYG) rating on Monday, October 19. WH Ireland has “Buy” rating and GBX 165 target. FinnCap maintained WYG PLC (LON:WYG) rating on Friday, November 24. FinnCap has “Buy” rating and GBX 80 target. On Thursday, October 6 the stock rating was maintained by N+1 Singer with “Corporate”. On Tuesday, September 29 the stock rating was maintained by WH Ireland with “Buy”. Sanlam Securities maintained the stock with “Buy” rating in Thursday, August 13 report. On Wednesday, August 30 the stock rating was maintained by FinnCap with “Buy”. See WYG PLC (LON:WYG) latest ratings:

04/12/2017 Broker: FinnCap Rating: Buy Old Target: GBX 50.00 New Target: GBX 50.00 Maintain 24/11/2017 Broker: FinnCap Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain 26/09/2017 Broker: FinnCap Rating: Buy Old Target: GBX 80.00 New Target: GBX 80.00 Maintain 30/08/2017 Broker: FinnCap Rating: Buy Old Target: GBX 124.00 New Target: GBX 80.00 Maintain 03/08/2017 Broker: FinnCap Rating: Buy New Target: GBX 124.00 Initiates Starts

Franklin Street Advisors Inc increased Jpmorgan Chase & Co (JPM) stake by 41.85% reported in 2017Q2 SEC filing. Franklin Street Advisors Inc acquired 43,991 shares as Jpmorgan Chase & Co (JPM)’s stock declined 6.04%. The Franklin Street Advisors Inc holds 149,101 shares with $13.63M value, up from 105,110 last quarter. Jpmorgan Chase & Co now has $363.54B valuation. The stock increased 0.26% or $0.27 during the last trading session, reaching $104.79. About 19.68 million shares traded or 59.74% up from the average. JPMorgan Chase & Co. (NYSE:JPM) has risen 33.74% since December 4, 2016 and is uptrending. It has outperformed by 17.04% the S&P500.

Among 32 analysts covering JPMorgan Chase & Co (NYSE:JPM), 17 have Buy rating, 2 Sell and 13 Hold. Therefore 53% are positive. JPMorgan Chase & Co had 88 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was reinitiated by UBS on Wednesday, January 11 with “Buy”. The rating was maintained by Keefe Bruyette & Woods on Friday, July 14 with “Hold”. BMO Capital Markets maintained the shares of JPM in report on Thursday, June 1 with “Hold” rating. The firm earned “Hold” rating on Friday, October 6 by BMO Capital Markets. The rating was downgraded by Macquarie Research to “Neutral” on Friday, September 9. The stock has “Buy” rating by Jefferies on Monday, October 10. The firm has “Buy” rating given on Monday, January 18 by Argus Research. The company was maintained on Wednesday, September 7 by Nomura. Nomura maintained the shares of JPM in report on Friday, October 13 with “Neutral” rating. On Friday, July 7 the stock rating was maintained by Jefferies with “Buy”.

Investors sentiment increased to 1.19 in Q2 2017. Its up 0.32, from 0.87 in 2017Q1. It improved, as 56 investors sold JPM shares while 678 reduced holdings. 146 funds opened positions while 731 raised stakes. 2.69 billion shares or 4.21% more from 2.58 billion shares in 2017Q1 were reported. Davis Selected Advisers holds 13.51M shares. Premier Asset Management Limited invested in 2.54% or 120,450 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1.22 million shares or 1.1% of its portfolio. 133,981 are owned by Brookmont Cap. Pineno Levin & Ford Asset Mgmt reported 0.1% stake. Boyar Asset Management reported 70,235 shares stake. Cue Fincl holds 4,957 shares or 0.33% of its portfolio. Alpha Cubed Investments Ltd Liability stated it has 143,611 shares. Freestone Capital Holdings Limited Liability holds 19,684 shares or 0.14% of its portfolio. United Kingdom-based Hermes Invest has invested 0.28% in JPMorgan Chase & Co. (NYSE:JPM). Etrade Mgmt Limited Com invested in 84,639 shares. Curbstone Mngmt Corp invested in 15,297 shares or 0.84% of the stock. Oak Ridge Invs Limited Com reported 4,235 shares. Optimum Invest Advisors, a Illinois-based fund reported 36,579 shares. Trust Of Vermont has 1.15% invested in JPMorgan Chase & Co. (NYSE:JPM).

Franklin Street Advisors Inc decreased Clorox Company (NYSE:CLX) stake by 7,464 shares to 30,815 valued at $4.11M in 2017Q2. It also reduced Calithera Biosciences Inc. (NASDAQ:CALA) stake by 40,000 shares and now owns 34,580 shares. Puma Biotechnology Inc (NYSE:PBYI) was reduced too.

The post Franklin Street Advisors Increased Its Jpmorgan Chase & Co (JPM) Position; WYG PLC (LON:WYG) Covered By 4 Bullish Analysts Last Week appeared first on Stock Market News | HillCountryTimes | Get it Today.

from Stock Market News | HillCountryTimes | Get it Today https://www.hillcountrytimes.com/2017/12/04/franklin-street-advisors-increased-its-jpmorgan-chase-wyg-plc-lonwyg-covered-by-4-bullish-analysts-last-week/

[nonviable-hostage]

via genetics - Google News